SABCS 2023
Dec 5 - 9, 2023 | San Antonio, TX
The agents listed below are currently under investigation. Their safety and efficacy have not been established.
Presentation
Vepdegestrant, a PROteolysis Targeting Chimera (PROTAC) Estrogen Receptor Degrader, Plus Palbociclib in Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase 1b CohortEP Hamilton et al.
Poster
Updated Results From VERITAC Evaluating Vepdegestrant, a PROteolysis Targeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in ER–Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast CancerSA Hurvitz et al.
Poster
TACTIVE-U: Phase 1b/2 Umbrella Study of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Combined With Other Anticancer Treatments in ER-Positive Advanced or Metastatic Breast CancerC Isaacs et al.
Poster
VERITAC-2: A Phase 3 Study of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, vs Fulvestrant in ER Positive/Human Epidermal Growth Factor Receptor 2 (HER2) Negative Advanced Breast CancerM Campone et al.
Poster
VERITAC-3: A Randomized Phase 3 Study, With a Lead in, of First Line Vepdegestrant + Palbociclib vs Letrozole + Palbociclib in Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast CancerSA Wander et al.
Poster
Leveraging a Pharmacokinetic/Pharmacodynamic (PK/PD) Model to Guide Dose Optimization of Palbociclib in Combination With VepdegestrantB Jermain et al.